Takeda Cancer Drug Extends Survival in Phase 3 Gastric Cancer Trial
MT newswire2026/10/23 12:11Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
08:11 AM EDT, 10/23/2026 (MT Newswires) -- Takeda Pharmaceutical (TAK) said Friday its experimental drug, arcotatug tavatecan, met both primary goals in a phase 3 trial involving certain patients with advanced gastric or gastroesophageal junction cancer. The company said the study showed that patients receiving the drug lived a median of 10.2 months, compared with 6.9 months for those receiving standard treatment. Median progression-free survival was 7.1 months versus 3.1 months, respectively, the company said. Takeda said the drug also achieved a 37.4% response rate, compared with 7.7% for standard treatment. The company said it plans to use the results to support a regulatory filing in Japan and advance global phase 3 trials in gastric and pancreatic cancer.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Crypto prices
MoreBitcoin
BTC
$63,700.8
-2.01%
Ethereum
ETH
$1,789.65
-1.74%
Tether USDt
USDT
$0.9988
-0.02%
BNB
BNB
$586.99
-0.47%
USDC
USDC
$0.9999
+0.02%
XRP
XRP
$0.9644
+0.83%
Solana
SOL
$72.75
+1.95%
TRON
TRX
$0.3072
+0.42%
Hyperliquid
HYPE
$67.85
-0.31%
Zcash
ZEC
$920.49
+2.81%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now